Last reviewed · How we verify
Dacryocystitis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Garamycin · Merck & Co.
- Tobi · Novartis
- Vantobra · Pfizer
- Gentamicin · Merck & Co.
- Nebcin · University Hospital, Lille
- Zithromax · Pfizer Inc.
Macrolide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with an exceptionally long tissue half-life. - Prelone · Generic (originally Schering)
- prednisolon · Hannover Medical School
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Dacryocystitis patent landscape — cliff calendar, originator estates, attackable patents
- Dacryocystitis treatment landscape brief
- Dacryocystitis treatment updates RSS
Frequently asked questions about Dacryocystitis
What drugs treat Dacryocystitis?
Tracked treatments include Ramycin, Garamycin, Tobi, Vantobra, Gentamicin, Nebcin, Zithromax, Prelone.
What is the treatment for Dacryocystitis?
Standard treatment for Dacryocystitis includes Ramycin, Garamycin, Tobi, Vantobra, Gentamicin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Dacryocystitis patent cliff · Dacryocystitis CI report
- Treatment: Ramycin
- Treatment: Garamycin · Merck & Co.
- Treatment: Tobi · Novartis
- Treatment: Vantobra · Pfizer
- Treatment: Gentamicin · Merck & Co.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing